Overview
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with extended half-life compared to native IGF-1. The modification reduces binding to IGF binding proteins, allowing for enhanced bioavailability and systemic activity over several hours, enabling once-daily dosing protocols in research applications.
What This Peptide Does
The peptide functions through IGF-1 receptor binding to support anabolic processes and metabolic function. Its extended circulation time maintains more stable plasma levels throughout the day compared to native IGF-1, which requires frequent dosing. However, it has never received FDA approval for human therapeutic use and remains restricted to research applications.
Reconstitution Instructions
Standard Protocol (3mL dilution):
– Draw 3.0 mL bacteriostatic water using a sterile syringe
– Inject slowly down the vial wall to avoid foaming; do not shake
– Gently swirl or roll until powder dissolves completely into clear solution
– Label vial with reconstitution date
– Refrigerate immediately at 2–8°C (35.6–46.4°F), protected from light
– Use within 30 days of reconstitution
Concentration achieved: ~0.333 mg/mL (333 mcg/mL)
Measurement conversion: At this concentration, 1 unit on a U-100 insulin syringe ≈ 3.33 mcg
Dosing Protocol
Gradual Titration Approach:
| Week | Daily Dose | Units on Syringe | Volume (mL) |
|---|---|---|---|
| 1–2 | 20 mcg | 6 units | 0.06 mL |
| 3–4 | 40 mcg | 12 units | 0.12 mL |
| 5–8 | 50 mcg | 15 units | 0.15 mL |
Administration Details:
– Frequency: Once daily via subcutaneous injection
– Timing: Morning or post-workout with food intake to manage insulin-like effects
– Duration: Standard 8-week cycle; may extend to 12 weeks with appropriate off-periods
– Conservative upper limit: 50 mcg/day (doses exceeding this threshold lack robust research support)
Site Rotation: Systematically alternate between abdomen (2+ inches from navel), outer thighs, and upper arms to prevent local irritation and lipohypertrophy.
Storage Requirements
Lyophilized (unopened vial):
– Optimal: −80°C (−112°F) or −20°C (−4°F) for up to 12 months
– Short-term: 2–8°C (35.6–46.4°F) acceptable for several months
– Keep in dry, dark conditions
Reconstituted Solution:
– Refrigerate at 2–8°C (35.6–46.4°F) immediately after mixing
– Use within 30 days for optimal potency
– For extended storage: prepare sterile aliquots and freeze at −20°C; stable for 3–6 months
– Never refreeze a thawed vial
Handling best practices: Allow frozen vials to reach room temperature before opening to minimize condensation. Always inspect for clarity; discard if cloudy or contains particles.
Cycling Recommendations
A common approach employs “8 weeks on, 4–8 weeks off” to prevent receptor desensitization. Studies suggest diminished returns beyond weeks 6–8 of continuous use, making periodic breaks advisable for protocol consistency.
Potential Research Observations
Reported effects in literature:
– Enhanced anabolic signaling and protein synthesis in target tissues
– Extended bioavailability compared to native IGF-1
– Metabolic effects through IGF-1 receptor pathways
Critical Safety Warnings
Hypoglycemia Risk: The most significant concern involves insulin-like effects on blood glucose. “Symptoms may include shakiness, confusion, sweating, or dizziness.” Always administer with food and maintain fast-acting carbohydrates readily available.
Regulatory Status: IGF-1 LR3 has never received FDA approval for human therapeutic use and is restricted to research applications only.
Additional considerations:
– Mild local irritation or injection site reactions may occur
– Safety concerns increase substantially at doses exceeding 50–60 mcg/day
– Receptor desensitization may develop with continuous use beyond 6–8 weeks
Injection Technique
Preparation:
– Wash hands thoroughly with soap and water
– Clean vial stopper with alcohol swab; allow complete air drying
– Verify reconstituted solution clarity; discard if cloudy
– Draw calculated dose into sterile insulin syringe (29–31 gauge, 1/2 inch needle)
– Remove air bubbles by gently tapping syringe
Administration:
– Select injection site with adequate subcutaneous fat (abdomen, thighs, upper arms)
– Clean site with alcohol swab; allow to dry completely
– Pinch skin fold between thumb and forefinger to ensure subcutaneous placement
– Insert needle at 45–90° angle into pinched skin
– Do not aspirate for subcutaneous injections
– Slowly depress plunger over 2–3 seconds
– Remove needle at same angle of entry
– Apply gentle pressure with clean cotton ball; do not rub vigorously
– Immediately dispose of syringe in sharps container without recapping
Supplies Needed (8-Week Protocol Example)
– Peptide Vials: 3 vials (1 mg each)
– Insulin Syringes: 56 syringes (U-100, 0.5 or 1 mL)
– Bacteriostatic Water: 1 x 10 mL bottle (provides 9 mL needed)
– Alcohol Swabs: 2 x 100-count boxes (112 swabs for 8 weeks)
– Sharps Container: For safe needle/syringe disposal
– Carbohydrate Source: Glucose tablets or juice for hypoglycemia management
Supporting Lifestyle Factors
– Nutrition: Maintain adequate protein intake (1.6–2.2 g/kg body weight); ensure regular meal timing for glucose stability
– Training: Combine with resistance training protocols; IGF-1 pathways activate through mechanical loading
– Sleep: Prioritize 7–9 hours nightly to optimize endogenous growth factor production
– Hydration: Maintain consistent hydration for metabolic function and peptide distribution
– Glucose monitoring: Consider periodic blood glucose checks during dose titration, especially if experiencing hypoglycemic symptoms
Important Notes
– Practice sterile technique: use new, sterile insulin syringes for each injection
– Follow “one needle, one syringe, only one time” safety protocol
– Keep detailed documentation of dose, injection site, and observed effects
– Never exceed conservative dosing guidelines; insufficient research supports higher doses
– This protocol is for research and educational purposes only
– Always consult qualified healthcare professionals before beginning any research protocol
Disclaimer
This information is provided for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. IGF-1 LR3 is restricted to research use and has not received FDA approval for human therapeutic applications.